Welcome to our dedicated page for Haemonetics Mass news (Ticker: HAE), a resource for investors and traders seeking the latest updates and insights on Haemonetics Mass stock.
Haemonetics Corporation (NYSE: HAE) delivers vital blood and plasma management solutions to healthcare providers worldwide. This page serves as the definitive source for official company announcements, financial updates, and innovation milestones.
Access timely updates on earnings reports, regulatory clearances, and strategic partnerships that shape HAE's leadership in medical technology. Investors will find press releases covering product launches like advanced diagnostic systems, operational expansions, and initiatives enhancing transfusion safety standards.
Our curated news collection helps stakeholders monitor developments across HAE's three core segments: plasma collection technologies, blood center optimization tools, and hospital transfusion management systems. Bookmark this page for direct access to filings, executive commentary, and progress updates on life-saving healthcare solutions.
Vivasure Medical has received CE Mark approval for its PerQseal Elite vascular closure system, a pioneering fully absorbable and sutureless large-bore vessel closure device. The product will be launched in select European markets this summer.
The PerQseal Elite system is specifically designed for closure following large-bore percutaneous cardiovascular procedures like TAVR and EVAR. It stands out as the first fully bioresorbable device in this category and requires no pre-procedure steps, offering improved procedural efficiency.
The device is placed from inside the vessel, providing simpler and more controlled deployment compared to conventional techniques. It restores the vessel to its natural state without leaving behind materials such as collagen, metal implants, or sutures.
Haemonetics (NYSE: HAE) has scheduled the release of its fourth quarter and fiscal year 2025 financial results for May 8, 2025 at 6:00 am ET. The company will host a conference call with investors and analysts at 8:00 am ET on the same day to discuss the results and address questions.
Participants can access the call via teleconference after completing registration, and are encouraged to join 10 minutes before the start time. A live webcast will be available on Haemonetics' investor relations website, with a replay accessible for one year starting May 8, 2025, at 11:00 am ET.
Haemonetics (NYSE: HAE) announced key executive leadership updates. Frank Chan, Ph.D. will join as Executive Vice President, Chief Operating Officer on April 7, 2025, while Roy Galvin has been appointed Executive Vice President, Chief Commercial Officer with immediate effect.
Chan, bringing over 25 years of medical device and healthcare technology leadership experience, will oversee research and development, regulatory affairs, global manufacturing, and supply chain operations. He joins from Medtronic plc, where he served as President of Acute Care & Monitoring.
Galvin, who joined Haemonetics in 2022 as President, Global Plasma and Blood Center, will now expand his responsibilities to include the Global Hospital business, directing all commercialization initiatives across the company's full product portfolio. He brings over 25 years of experience from Medtronic plc in the Neuroscience and Orthopedic markets.
Haemonetics (NYSE: HAE) has announced its participation in the upcoming Raymond James 46th Annual Institutional Investors Conference. Chris Simon, President and CEO, will engage in a fireside chat with investors on Tuesday, March 4, 2025, at 2:50 p.m. ET.
The event will be accessible to the public through a live webcast on Haemonetics' Investor Relations website and via a dedicated link. Following the presentation, a replay will be made available approximately 12 hours after the event and will remain accessible for 90 days through the company's Investor Relations website.
Haemonetics (NYSE: HAE) has announced the availability of its third quarter fiscal year 2025 financial results for the period ended December 28, 2024, on its Investor Relations website. The company will host a conference call and webcast with investors and analysts on February 6, 2025, at 8:00 a.m. ET to discuss the results.
Participants can access the teleconference through registration and will receive a dial-in number with a personalized PIN. A live webcast is also available on Haemonetics' investor relations website. The company has posted the earnings release that will be referenced during the call on their website. A replay of the conference call and webcast will be accessible for one year starting February 6, 2025, at 11:00 a.m. ET.
Haemonetics (NYSE: HAE) has completed the sale of its whole blood assets to GVS, S.p.A for a total consideration of up to $67.8 million. The deal includes $45.3 million upfront payment and potential earn-outs of up to $22.5 million over four years.
The transaction encompasses Haemonetics' whole blood collection, processing and filtration solutions portfolio, along with its Covina, California manufacturing facility and related assets in Tijuana, Mexico. The company plans to use the proceeds for general corporate purposes and growth initiatives.
Haemonetics will maintain its Blood Center business, continuing to manufacture and provide apheresis solutions for automated blood collection, including devices and disposable kits for platelets, plasma, and red cells collection.
Haemonetics (NYSE: HAE) has announced it will release its third quarter fiscal year 2025 financial results on Thursday, February 6, 2025 at 6:00 am ET. The company will host a conference call with investors and analysts at 8:00 am ET on the same day to discuss the results and address questions.
Participants can access the call via teleconference after completing registration, and are encouraged to join 10 minutes before the start. A live webcast will be available on Haemonetics' investor relations website, with both the conference call and webcast replay accessible for one year starting February 6, 2025, at 11:00 am ET.
Haemonetics (NYSE: HAE) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Chris Simon, President and CEO, is scheduled to present on Tuesday, January 14, 2025, at 5:15 pm Pacific Time.
The presentation will be accessible to the public through a live audio webcast via the conference platform and through Haemonetics' Investor Relations website under the Events & Presentations section. A replay of the presentation will remain available for 30 days following the event, accessible through both platforms approximately one hour after the live presentation concludes.
Haemonetics (NYSE: HAE) has announced the sale of its whole blood assets to GVS, S.p.A for up to $67.1M, including $44.6M upfront and potential earn-outs of $22.5M over four years. The deal includes Haemonetics' whole blood collection, processing and filtration solutions, along with manufacturing facilities in Covina, California and related assets in Tijuana, Mexico. The transaction is expected to close in Q1 2025.
Haemonetics will continue its Blood Center business, manufacturing apheresis solutions for automated blood collection. This move aligns with the company's strategy to focus on commercial and non-commercial plasma leadership and expand in high-growth hospital markets.
Haemonetics (NYSE: HAE) announced the availability of its second quarter fiscal year 2025 financial results, ended September 28, 2024, on its Investor Relations website. The company will host a conference call and webcast with investors and analysts on November 7, 2024, at 8:00 a.m. ET to discuss the results. Participants are recommended to join 10 minutes before the event starts. A replay of the conference call and webcast will be available for one year starting November 7, 2024, at 11:00 a.m. ET.
